EXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (OTCBB: FCSC), a biotechnology company focused on the development of autologous (personalized) cell therapies for aesthetic, medical and scientific applications, announced yesterday that it has entered into a scientific collaboration with University of California, Los Angeles (UCLA) to research the conversion of dermal fibroblasts into pure functional human cell types that may have greater regenerative capacity. In addition, Fibrocell announces they have accessed key patents from Stanford University to enable the process.
